|(a) Informed consent for treatment with a psychoactive medication will be obtained in accordance with the provisions of Chapter 414, Subchapter I of this title (relating to Consent to Treatment with Psychoactive Medication - Mental Health Facilities) or Chapter 405, Subchapter I of this title (relating to Consent to Treatment with Psychotropic Medication - Mental Retardation Facilities), as appropriate. (b) The use of PRN medication requires an appropriate consent process in accordance with the provisions referred to in subsection (a) of this section. (c) The service setting will provide individual and group medication education when appropriate to patients, their families, and LARs according to accepted guidelines (e.g., TIMA patient and family education guidelines). If accepted guidelines do not exist, the education will discuss characteristics of the medication, including expected benefits, potential adverse or side effects, dosage, standard alternative treatments, legal rights, and any questions the patient, family, or LAR may have. Education is also provided to address significant changes in the patient's medication regimen. (d) The service setting will have policies and procedures to address medication education and documentation standards.